TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33479925

Group type: EXPERIMENTAL
Intervention: Communication about interval hypoglycemia
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Reporting of hypoglycemic events
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hypoglycemia anticipatory guidance
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Counseling on hypoglycemia treatment or avoidance of driving
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Discussions of hypoglycemia unawareness
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Documentation in visit notes
Number of subjects: 33
Study: 33059756

Group type: EXPERIMENTAL
Intervention: Ivermectin-albendazole
Number of subjects: 320

Group type: COMPARATOR
Intervention: Kato-Katz
Number of subjects: 320
Study: 36137638

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) and prednisolone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous human albumin (5%) and placebo tablets
Number of subjects: 74
Study: 36469739

Group type: EXPERIMENTAL
Intervention: Detergent and water
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Commercial skin wipes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no decontamination)
Number of subjects: 88
Study: 33445809

Group type: EXPERIMENTAL
Intervention: Consumption of trans fatty acids (TFAs)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Sources of TFAs in the diet
Number of subjects: 1248
Study: 32005604

Group type: EXPERIMENTAL
Intervention: Experimental group received a head turban, sleeping socks, a heated blanket, a Bair Hugger for forced-air warming, and a Mega Acer kit for warming intravenous fluid.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group received a typical hospital cotton blanket.
Number of subjects: 54
Study: 32564571

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg bid
Number of subjects: 61

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg qd
Number of subjects: 61
Study: 32665433

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Guselkumab (after crossover from placebo)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 149
Study: 35700523

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogue lash lengtheners (PGALLs) containing isopropyl cloprostenate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-prostaglandin analogue lash lengtheners (NPGALLs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: False eyelashes (FLs)
Number of subjects: 15
Study: 33150481

Group type: EXPERIMENTAL
Intervention: miR-367 treatment in erythrocyte lysate-treated microglia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-367 mimic in the presence of CEBPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 36402857

Group type: EXPERIMENTAL
Intervention: Combined laser iridoplasty followed by surgical iridectomy (LI-SI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 67
Study: 32152145

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF) treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (sham eyes)
Number of subjects: 51
Study: 33006400

Group type: EXPERIMENTAL
Intervention: Immediate colposcopy (IC)
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: hrHPV testing (HPV)
Number of subjects: 2661

Group type: COMPARATOR
Intervention: Conventional cytology at 6 and 12 months (RC)
Number of subjects: 2661
Study: 34799125

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 33678496

Group type: EXPERIMENTAL
Intervention: Animation (n = 212)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Leaflet with images (n = 197)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Leaflet with text only (n = 197)
Number of subjects: 606
Study: 32083646

Group type: EXPERIMENTAL
Intervention: β‐carotene + fermented milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Carrot + fermented milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tomato + fermented milk
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Spinach + fermented milk
Number of subjects: 16

Group type: COMPARATOR
Intervention: β‐carotene only
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carrot drink alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tomato drink alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spinach drink alone
Number of subjects: 16
Study: 33100326

Group type: EXPERIMENTAL
Intervention: HDL increase (1 SD = 12.26 mg/dL)
Number of subjects: 69374

Group type: EXPERIMENTAL
Intervention: TG increase (1 SD = 112.33 mg/dL)
Number of subjects: 69374
Study: 32171780

Group type: EXPERIMENTAL
Intervention: Think/No‐Think task with food specific cues
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher emotional eating
Number of subjects: 61
Study: 33875433

Group type: EXPERIMENTAL
Intervention: NTM-1632 (0.033 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTM-1632 (0.165 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTM-1632 (0.330 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study: 33568226

Group type: EXPERIMENTAL
Intervention: Encapsulated iodine complex of 200 mg (arm A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iodine complex syrup form 40 ml (arm B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Iodine complex throat spray of 2 puffs (arm C)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Empty capsule (arm D) as placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All arms (A, B, C, D)
Number of subjects: 200
Study: 33044292

Group type: EXPERIMENTAL
Intervention: Stapled colonic J-pouch
Number of subjects: 379

Group type: COMPARATOR
Intervention: Straight colorectal anastomosis
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 379
Study: 35445723

Group type: EXPERIMENTAL
Intervention: Pixantrone 180 mg/m2 every 3 weeks (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pixantrone 85 mg/m2 on days 1, 8, and 15 of a 28-day cycle (group B)
Number of subjects: 45
Study: 34499820

Group type: EXPERIMENTAL
Intervention: Albuterol nebulized with 3% hypertonic saline (HSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Albuterol nebulized with normal saline solution (NSS)
Number of subjects: 50
Study: 32169140

Group type: EXPERIMENTAL
Intervention: Blended Learning (BL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Lecturing (TL)
Number of subjects: 0
Study: 35239778

Group type: EXPERIMENTAL
Intervention: Traction therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional therapy
Number of subjects: 96
Study: 33070249

Group type: EXPERIMENTAL
Intervention: Rh‐endostatin plus paclitaxel/nedaplatin
Number of subjects: 53
Study: 33550546

Group type: EXPERIMENTAL
Intervention: Capno + group (nurses managed patients with access to the capnometer and PETCO2 measurements)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Capno - group (nurses monitored patients without seeing PETCO2 measurements)
Number of subjects: 48
Study: 34540780

Group type: EXPERIMENTAL
Intervention: Yoga program for T2DM prevention (YOGA-DP)
Number of subjects: 14
Study: 36104128

Group type: EXPERIMENTAL
Intervention: Oral intake of LC-Plasma-containing capsule, 200 mg/day, for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo capsule, for 14 days
Number of subjects: 100
Study: 34441810

Group type: EXPERIMENTAL
Intervention: Breathing intervention (yoga-based breathing intervention)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 33163715

Group type: EXPERIMENTAL
Intervention: Modified low-phosphorus diet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard low-phosphorus diet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 74
Study: 35216868

Group type: EXPERIMENTAL
Intervention: Regulation of Craving Training (ROC-T)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 93
Study: 34229051

Group type: EXPERIMENTAL
Intervention: NIMO‐CCRT (CCRT with 200 mg of nimotuzumab administered weekly by intravenous infusion)
Number of subjects: 122

Group type: COMPARATOR
Intervention: CCRT (65 Gy thoracic radiation over 5 weeks concurrent with docetaxel and cisplatin)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: NIMO‐CCRT
Number of subjects: 122

Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 122
Study: 33638104

Group type: EXPERIMENTAL
Intervention: Robotic-assisted cholecystectomy (RAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 40
Study: 33253664

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection 2 mg every 4 weeks (2q4)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injection 2 mg every 8 weeks (2q8)
Number of subjects: 113
Study: 34013755

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stretching and toning (SAT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: AET
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 35945514

Group type: EXPERIMENTAL
Intervention: Preoperative anal dilatation using a 33 mm anal dilator for 20 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: No preoperative anal dilatation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative anal dilatation
Number of subjects: 40
Study: 33759389

Group type: EXPERIMENTAL
Intervention: Phenotype-guided treatment with antiobesity medications (phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, liraglutide)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-phenotype-guided treatment with antiobesity medications
Number of subjects: 450
Study: 35978437

Group type: EXPERIMENTAL
Intervention: AR-based digital healthcare system
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 115
Study: 33691612

Group type: EXPERIMENTAL
Intervention: RicePro (2×20g of protein)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: WheyPro (2×20g of protein)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 70
Study: 32031726

Group type: EXPERIMENTAL
Intervention: Intralesional injection of MMR vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 48
Study: 33550239

Group type: EXPERIMENTAL
Intervention: Operation with 3D printed patient-specific jig
Number of subjects: 36

Group type: COMPARATOR
Intervention: Operation without jig
Number of subjects: 36
Study: 32664987

Group type: EXPERIMENTAL
Intervention: Baby-Friendly Community Initiative (BFCI) intervention with 12 personalized home-based counselling sessions
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Baby-Friendly Community Initiative (BFCI) intervention
Number of subjects: 901
Study: 36308244

Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infraclavicular block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (non-blocked arm)
Number of subjects: 40
Study: 34379090

Group type: EXPERIMENTAL
Intervention: Omnigenic Mendelian randomization (OMR) method using all genome-wide SNPs for causal inference
Number of subjects: 0
Study: 34260542

Group type: EXPERIMENTAL
Intervention: Deferred Stenting (DS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Immediate Stenting (IS)
Number of subjects: 114
Study: 32332810

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health Education (HE) for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 40
Study: 35184629

Group type: EXPERIMENTAL
Intervention: WeChat-based Dyadic Life Review Program
Number of subjects: 47
Study: 34000607

Group type: EXPERIMENTAL
Intervention: Drive and Retrieve System (DRS) with an additional neurointerventionist allocated for DRS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current scenario (control) where patients received endovascular thrombectomy in facilities where specialists normally work
Number of subjects: 0
Study: 32191328

Group type: EXPERIMENTAL
Intervention: Lottery prize amount won (ranging from $0 to $1.6 million)
Number of subjects: 4820
Study: 36041708

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg on days 1-7, 0.5 mg on days 8-14
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg per day for 14 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Colchicine 2 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Colchicine 3 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Number of subjects: 39
Study: 33704936

Group type: EXPERIMENTAL
Intervention: One-step screening (75-g glucose load, fasting state)
Number of subjects: 23792

Group type: COMPARATOR
Intervention: Two-step screening (50-g glucose load, nonfasting state followed by 100-g glucose load, fasting state)
Number of subjects: 23792

Group type: EXPERIMENTAL
Intervention: One-step screening
Number of subjects: 23792

Group type: COMPARATOR
Intervention: Two-step screening
Number of subjects: 23792
Study: 32856709

Group type: EXPERIMENTAL
Intervention: Low salt diet (1,500 mg/d)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Medium salt diet (2,400 mg/d)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: High salt diet (3,300 mg/d)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Uromodulin levels
Number of subjects: 157
Study: 35378544

Group type: EXPERIMENTAL
Intervention: Intensive mirror therapy (5 times/week for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spaced mirror therapy (3 times/week for 10 weeks)
Number of subjects: 40
Study: 33128635

Group type: EXPERIMENTAL
Intervention: Prediction model for vitamin D deficiency based on clinical characteristics
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: Non-European ethnicity
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis using deseasonalised serum 25OHD (DS‐25OHD) as the dependent variable
Number of subjects: 4073

Group type: EXPERIMENTAL
Intervention: DS‐25OHD < 40 nmol/L
Number of subjects: 4073
Study: 35050697

Group type: EXPERIMENTAL
Intervention: Spanish support intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Spanish support control
Number of subjects: 56
Study: 35230249

Group type: EXPERIMENTAL
Intervention: Community volunteers (CVs) tracking children's vaccination status and demographic movements, organizing monthly catch-up immunization sessions via WhatsApp.
Number of subjects: 1260
Study: 33394039

Group type: EXPERIMENTAL
Intervention: Ultrasound surveillance
Number of subjects: 95
Study: 33632035

Group type: EXPERIMENTAL
Intervention: Fear of COVID-19
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Anxiety of COVID-19
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Perceived Stress
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Self-Care
Number of subjects: 215
Study: 34881436

Group type: EXPERIMENTAL
Intervention: In-person family contact
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Text/email/letter with friends
Number of subjects: 155
Study: 33355947

Group type: EXPERIMENTAL
Intervention: Unilateral ACP (Group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bilateral ACP (Group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 42
Study: 33086145

Group type: EXPERIMENTAL
Intervention: Real hf-tRNS (100–650 Hz)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham hf-tRNS
Number of subjects: 40
Study: 35509819

Group type: EXPERIMENTAL
Intervention: Red ginseng formulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Red ginseng formulation with 1,2‐hexanediol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrogel application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrogel formulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall microbial species
Number of subjects: 20
Study: 32890813

Group type: EXPERIMENTAL
Intervention: Gemcitabine + Sorafenib (GemSorafenib)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Gemcitabine + Placebo (GemP)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (more than six cycles)
Number of subjects: 122
Study: 34695622

Group type: EXPERIMENTAL
Intervention: Mechanical method (balloon catheter)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Pharmaceutical method (prostaglandins)
Number of subjects: 74
Study: 33734765

Group type: EXPERIMENTAL
Intervention: Strength at Home (SAH) intervention
Number of subjects: 23
Study: 33367539

Group type: EXPERIMENTAL
Intervention: Orthodontic space closure treatment (TG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study: 32074652

Group type: EXPERIMENTAL
Intervention: TKA with a tourniquet
Number of subjects: 65

Group type: COMPARATOR
Intervention: TKA without a tourniquet
Number of subjects: 65
Study: 32613752

Group type: EXPERIMENTAL
Intervention: Cinpanemab (BIIB054) 250 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinpanemab (BIIB054) 1,250 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinpanemab (BIIB054) 3,500 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinpanemab (BIIB054) up to 90 mg/kg
Number of subjects: 0
Study: 35007684

Group type: EXPERIMENTAL
Intervention: Ustukhuddus Alavi
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 34334739

Group type: EXPERIMENTAL
Intervention: 1-year TST follow-up
Number of subjects: 1770

Group type: EXPERIMENTAL
Intervention: 2-year TST follow-up
Number of subjects: 1770
Study: 32619413

Group type: EXPERIMENTAL
Intervention: Laparoscopic ileocaecal resection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Immunomodulator therapy (in addition to allocated treatment)
Number of subjects: 134
Study: 35902900

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prebiotic treatment 1, 2, and 3
Number of subjects: 0
Study: 33097554

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of local anaesthetic
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous analgesia with or without sedation
Number of subjects: 11
Study: 35210352

Group type: EXPERIMENTAL
Intervention: Bedtime antihypertensive administration
Number of subjects: 3227

Group type: COMPARATOR
Intervention: Morning antihypertensive administration
Number of subjects: 3227
Study: 35175183

Group type: EXPERIMENTAL
Intervention: Galileo NEO automated method
Number of subjects: 700

Group type: COMPARATOR
Intervention: Manual CAT method
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Manual DTT-treated IgG
Number of subjects: 700
Study: 34887851

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) and Blank control
Number of subjects: 54
Study: 35799298

Group type: EXPERIMENTAL
Intervention: Structured Health Intervention For Truckers (SHIFT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 382
Study: 33646046

Group type: EXPERIMENTAL
Intervention: Simple priming with the definition of DFs and information about their potentially harmful applications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deepfake recognition
Number of subjects: 0
Study: 32862009

Group type: EXPERIMENTAL
Intervention: Anodal treatment group (tsDCS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment group
Number of subjects: 30
Study: 35915187

Group type: EXPERIMENTAL
Intervention: Laparoscopic Fundoplication (LF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open Fundoplication (OF)
Number of subjects: 88
Study: 33865501

Group type: EXPERIMENTAL
Intervention: Teprotumumab (10 mg/kg body weight for the first infusion, 20 mg/kg for subsequent infusions, administered every 3 weeks for a total of 8 infusions)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 33514774

Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium animalis lactis and fructo‐oligosaccharides (FOS))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32854693

Group type: EXPERIMENTAL
Intervention: Investigational device using pulsating force
Number of subjects: 28

Group type: COMPARATOR
Intervention: Invisalign treatment (Control)
Number of subjects: 28
Study: 84056285

Group type: EXPERIMENTAL
Intervention: 20 mg oral diazepam and supportive care (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo and supportive care (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Further (unblinded) diazepam, 20 mg, every 1 to 2 hr for non-responders (n = 18)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam doses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo during the experimental phase
Number of subjects: 50
Study: 35065063

Group type: COMPARATOR
Intervention: Ceftriaxone (500 mg, intramuscular)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Ertapenem (1000 mg, intramuscular)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Gentamicin (5 mg/kg, maximum 400 mg, intramuscular)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Fosfomycin (6 g, oral)
Number of subjects: 346